Imaging preclinical tumour models: Improving translational power

Nature Reviews Cancer

Volumn 14, Issue 7, 2014, Pages 481-493

  De Jong, Marion ^a   Essers, Jeroen ^b   Van Weerden, Wytske M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Cancer Genomics Centre   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE;

CANCER RESEARCH; HUMAN; MOLECULAR PROBE; MULTIMODAL IMAGING; NONHUMAN; PRIORITY JOURNAL; REVIEW; TECHNOLOGY; TRANSLATIONAL RESEARCH; TUMOR MODEL; TUMOR XENOGRAFT; ANIMAL WELFARE; BASIC RESEARCH; BIOLUMINESCENCE; CANCER MODEL; COMPUTER ASSISTED TOMOGRAPHY; EX VIVO STUDY; EXPERIMENTAL DESIGN; EXPERIMENTAL MOUSE; FLUORESCENCE IMAGING; IN VIVO STUDY; MICROSCOPY; MOLECULAR IMAGING; NOD SCID GAMMA MOUSE; NOD SCID MOUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; SCID BEIGE MOUSE; SCID MOUSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNTHESIS; ULTRASOUND;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MOLECULAR IMAGING; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84903317271     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3751     Document Type: Review

References (174)

1. Cook, N., Jodrell, D. I. & Tuveson, D. A. Predictive in vivo animal models and translation to clinical trials. Drug Discov. Today 17, 253-260 (2012
2. Heyer, J., Kwong, L. N., Lowe, S. W. & Chin, L. Non-germline genetically engineered mouse models for translational cancer research. Nature Rev. Cancer 10, 470-480 (2010
3. Langdon, S. P. Animal modeling of cancer pathology and studying tumor response to therapy. Curr. Drug Targets 13, 1535-1547 (2012
4. Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nature Rev. Clin. Oncol. 9, 338-350 (2012). This review highlights the opportunities and limitations of PDX models in cancer drug development and describes concepts regarding predictive biomarker development and future applications.
5. Konantz, M. et al. Zebrafish xenografts as a tool for in vivo studies on human cancer. Ann. N. Y. Acad. Sci. 1266, 124-137 (2012
6. Leong, H. S., Chambers, A. F. & Lewis, J. D. Assessing cancer cell migration and metastatic growth in vivo in the chick embryo using fluorescence intravital imaging. Methods Mol. Biol. 872, 1-14 (2012
7. Mimeault, M. & Batra, S. K. Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials. Drug Discov. Today 18, 128-140 (2012
8. Vaira, V. et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc. Natl Acad. Sci. USA 107, 8352-8356 (2010
9. van der Kuip, H. et al. Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer 6, 86 (2006
10. Graves, E. E., Weissleder, R. & Ntziachristos, V. Fluorescence molecular imaging of small animal tumor models. Curr. Mol. Med. 4, 419-430 (2004
11. Massoud, T. F. & Gambhir, S. S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 17, 545-580 (2003
12. Weissleder, R. & Mahmood, U. Molecular imaging. Radiology 219, 316-333 (2001
13. Timpson, P., McGhee, E. J. & Anderson, K. I. Imaging molecular dynamics in vivo-from cell biology to animal models. J. Cell Sci. 124, 2877-2890 (2011
14. Ntziachristos, V. Going deeper than microscopy: the optical imaging frontier in biology. Nature Methods 7, 603-614 (2010
15. Massoud, T. F. & Gambhir, S. S. Integrating noninvasive molecular imaging into molecular medicine: an evolving paradigm. Trends Mol. Med. 13, 183-191 (2007
16. Pichler, B. J., Wehrl, H. F. & Judenhofer, M. S. Latest advances in molecular imaging instrumentation. J. Nucl. Med. 49 (Suppl 2), 5S-23S (2008
17. Condeelis, J. & Weissleder, R. In vivo imaging in cancer. Cold Spring Harb. Perspect. Biol. 2, a003848 (2010). This paper gives an overview of current macroscopic and microscopic imaging technologies aimed at the translation of basic molecular insight at the single cell level to clinical applications.
18. Cai, W. & Chen, X. Nanoplatforms for targeted molecular imaging in living subjects. Small 3, 1840-1854 (2007
19. Goldenberg, D. M., Rossi, E. A., Sharkey, R. M., McBride, W. J. & Chang, C. H. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J. Nucl. Med. 49, 158-163 (2008
20. Schottelius, M. & Wester, H. J. Molecular imaging targeting peptide receptors. Methods 48, 161-177 (2009
21. Zhang, Z. et al. Activatable molecular systems using homologous near-infrared fluorescent probes for monitoring enzyme activities in vitro, in cellulo, and in vivo. Mol. Pharm. 6, 416-427 (2009
22. Lofblom, J. et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 584, 2670-2680 (2010
23. Olafsen, T. & Wu, A. M. Antibody vectors for imaging. Semin. Nucl. Med. 40, 167-181 (2010
24. Godin, B., Tasciotti, E., Liu, X., Serda, R. E. & Ferrari, M. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc. Chem. Res. 44, 979-989 (2011
25. Jokerst, J. V. & Gambhir, S. S. Molecular imaging with theranostic nanoparticles. Acc. Chem. Res. 44, 1050-1060 (2011
26. Devoogdt, N. et al. Molecular imaging using nanobodies: a case study. Methods Mol. Biol. 911, 559-567 (2012
27. Gulyas, B. & Halldin, C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q. J. Nucl. Med. Mol. Imag. 56, 173-190 (2012
28. Laverman, P., Sosabowski, J. K., Boerman, O. C. & Oyen, W. J. Radiolabelled peptides for oncological diagnosis. Eur. J. Nucl. Med. Mol. Imag. 39 (Suppl. 1), S78-S92 (2012
29. Olafsen, T., Sirk, S. J., Olma, S., Shen, C. K. & Wu, A. M. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumour Biol. 33, 669-677 (2012
30. Tran Cao, H. S. et al. Tumor-specific fluorescence antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer. Hepatogastroenterology 59, 1994-1999 (2012
31. Weissleder, R. & Pittet, M. J. Imaging in the era of molecular oncology. Nature 452, 580-589 (2008
32. Arosio, D., Casagrande, C. & Manzoni, L. Integrin-mediated drug delivery in cancer and cardiovascular diseases with peptide-functionalized nanoparticles. Curr. Med. Chem. 19, 3128-3151 (2012
33. Deshpande, N., Needles, A. & Willmann, J. K. Molecular ultrasound imaging: current status and future directions. Clin. Radiol. 65, 567-581 (2010
34. Lee, J. H. et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nature Med. 13, 95-99 (2007
35. Kiessling, F., Fokong, S., Koczera, P., Lederle, W. & Lammers, T. Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics. J. Nucl. Med. 53, 345-348 (2012
36. Karmakar, A. et al. Raman spectroscopy as a detection and analysis tool for in vitro specific targeting of pancreatic cancer cells by EGF-conjugated, single-walled carbon nanotubes. J. Appl. Toxicol. 32, 365-375 (2012
37. Ciarlo, M. et al. Use of the semiconductor nanotechnologies "quantum dots" for in vivo cancer imaging. Recent Pat. Anticancer Drug Discov. 4, 207-215 (2009
38. Kiessling, F. Science to practice: the dawn of molecular US imaging for clinical cancer imaging. Radiology 256, 331-333 (2010
39. Kluza, E. et al. Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J. Control Release 158, 207-214 (2012
40. Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R. & Tsourkas, A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338, 903-910 (2012
41. Martic-Kehl, M. I., Schibli, R. & Schubiger, P. A. Can animal data predict human outcome? Problems and pitfalls of translational animal research. Eur. J. Nucl. Med. Mol. Imaging 39, 1492-1496 (2012
42. van der Worp, H. B. et al. Can animal models of disease reliably inform human studies? PLoS Med. 7, e1000245 (2010
43. Begley, C. G. & Ellis, L. M. Drug development: Raise standards for preclinical cancer research. Nature 483, 531-533 (2012
44. Perel, P. et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ 334, 197 (2007
45. Hackam, D. G. & Redelmeier, D. A. Translation of research evidence from animals to humans. JAMA 296, 1731-1732 (2006
46. Koba, W., Jelicks, L. A. & Fine, E. J. MicroPET/SPECT/CT imaging of small animal models of disease. Am. J. Pathol. 182, 319-324 (2013
47. de Kemp, R. A., Epstein, F. H., Catana, C., Tsui, B. M. & Ritman, E. L. Small-animal molecular imaging methods. J. Nucl. Med. 5, (Suppl 1), 18S-32S (2010
48. Shcherbakova, D. M. & Verkhusha, V. V. Near-infrared fluorescent proteins for multicolor in vivo imaging. Nature Methods 10, 751-754 (2013
49. van Dam, G. M. et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-γ targeting: first in-human results. Nature Med. 17, 1315-1319 (2011
50. Brouwer, O. R. et al. Comparing the hybrid fluorescent-radioactive tracer indocyanine green-99mTc-nanocolloid with 99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy and SPECT/CT. J. Nucl. Med. 53, 1034-1040 (2012
51. Buckle, T., Brouwer, O. R., Valdes Olmos, R. A., van der Poel, H. G. & van Leeuwen, F. W. Relationship between intraprostatic tracer deposits and sentinel lymph node mapping in prostate cancer patients. J. Nucl. Med. 53, 1026-1033 (2012
52. Buckle, T., Chin, P. T. & van Leeuwen, F. W. (Non-targeted) radioactive/fluorescent nanoparticles and their potential in combined pre-and intraoperative imaging during sentinel lymph node resection. Nanotechnology 21, 482001 (2010
53. Filonov, G. S. et al. Bright and stable near-infrared fluorescent protein for in vivo imaging. Nature Biotech. 29, 757-761 (2011
54. Hoffman, R. M. Cellular and subcellular imaging in live mice using fluorescent proteins. Curr. Pharm. Biotechnol. 13, 537-544 (2012
55. Kelkar, M. & De, A. Bioluminescence based in vivo screening technologies. Curr. Opin. Pharmacol. 12, 592-600 (2012
56. O?Neill, K., Lyons, S. K., Gallagher, W. M., Curran, K. M. & Byrne, A. T. Bioluminescent imaging: a critical tool in pre-clinical oncology research. J. Pathol. 220, 317-327 (2010
57. Kim, J. B. et al. Non-invasive detection of a small number of bioluminescent cancer cells in vivo. PLoS ONE 5, e9364 (2010
58. Hoffman, R. M. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nature Rev. Cancer 5, 796-806 (2005
59. Timpson, P. et al. Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53. Cancer Res. 71, 747-757 (2011
60. Kiessling, F. & Pichler, B. Small animal imaging. Basics and practical guide., (Springer, 2012
61. Rossin, R. et al. In vivo chemistry for pretargeted tumor imaging in live mice. Angew. Chem. Int. Ed. Engl. 49, 3375-3378 (2010
62. Elsabahy, M. & Wooley, K. L. Design of polymeric nanoparticles for biomedical delivery applications. Chem. Soc. Rev. 41, 2545-2561 (2012
63. Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nature Rev. Drug Discov. 9, 615-627 (2010
64. Brader, P., Serganova, I. & Blasberg, R. G. Noninvasive molecular imaging using reporter genes. J. Nucl. Med. 54, 167-172 (2013
65. Ray, P. & De, A. Reporter gene imaging in therapy and diagnosis. Theranostics 2, 333-334 (2012
66. Pool, S. E., ten Hagen, T. L., Koelewijn, S., de Jong, M. & Koning, G. A. Multimodality imaging of somatostatin receptor-positive tumors with nuclear and bioluminescence imaging. Mol. Imag. 11, 27-32 (2012
67. Schroeder, R. P., van Weerden, W. M., Bangma, C., Krenning, E. P. & de Jong, M. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods 48, 200-204 (2009
68. Stelter, L. et al. An orthotopic model of pancreatic somatostatin receptor (SSTR)-positive tumors allows bimodal imaging studies using 3T MRI and animal PET-based molecular imaging of SSTR expression. Neuroendocrinology 87, 233-242 (2008
69. Kang, J. H. & Chung, J. K. Molecular-genetic imaging based on reporter gene expression. J. Nucl. Med. 49, (Suppl 2) 164S-179S (2008
70. Chua, S., Gnanasegaran, G. & Cook, G. J. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. Semin. Nucl. Med. 39, 416-430 (2009
71. Vandsburger, M. H., Radoul, M., Cohen, B. & Neeman, M. MRI reporter genes: applications for imaging of cell survival, proliferation, migration and differentiation. NMR Biomed. 24, 872-884 (2012
72. Cohen, B. et al. MRI detection of transcriptional regulation of gene expression in transgenic mice. Nature Med. 13, 498-503 (2007
73. Gilad, A. A. et al. MRI reporter genes. J. Nucl. Med. 49, 1905-1908 (2008
74. Avni, R., Cohen, B. & Neeman, M. Hypoxic stress and cancer: imaging the axis of evil in tumor metastasis. NMR Biomed. 24, 569-581 (2011
75. Cai, W., Niu, G. & Chen, X. Imaging of integrins as biomarkers for tumor angiogenesis. Curr. Pharm. Des. 14, 2943-2973 (2008
76. Roivainen, A., Jalkanen, S. & Nanni, C. Gallium-labelled peptides for imaging of inflammation. Eur. J. Nucl. Med. Mol. Imag. 39 (Suppl. 1), S68-S77 (2012
77. de Jong, M., Breeman, W. A., Kwekkeboom, D. J., Valkema, R. & Krenning, E. P. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc. Chem. Res. 42, 873-880 (2009). This study is an example of the theranostic concept using radiopeptides.
78. Ambrosini, V., Fani, M., Fanti, S., Forrer, F. & Maecke, H. R. Radiopeptide imaging and therapy in Europe. J. Nucl. Med. 52, (Suppl 2), 42S-55S (2011
79. Kwekkeboom, D. J. et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 26, 2124-2130 (2008
80. Louie, A. Multimodality imaging probes: design and challenges. Chem. Rev. 110, 3146-3195 (2010
81. Zhang, L. et al. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83, 761-769 (2008
82. Bednar, B. & Ntziachristos, V. Opto-acoustic imaging of drug discovery biomarkers. Curr. Pharm. Biotechnol. 13, 2117-2127 (2012
83. Kenny, G. D. et al. Multifunctional receptor-targeted nanocomplexes for magnetic resonance imaging and transfection of tumours. Biomaterials 33, 7241-7250 (2012
84. Xu, C. & Zhao, W. Nanoparticle-based monitoring of stem cell therapy. Theranostics 3, 616-617 (2013
85. Agasti, S. S. et al. Dual imaging and photoactivated nanoprobe for controlled cell tracking. Small 9, 222-227 (2013
86. Kircher, M. F., Gambhir, S. S. & Grimm, J. Noninvasive cell-tracking methods. Nature Rev. Clin. Oncol. 8, 677-688 (2011). This paper provides an overview of the basic principles of cell-tracking methods.
87. Srinivas, M. et al. Imaging of cellular therapies. Adv. Drug Deliv. Rev. 62, 1080-1093 (2010
88. Rygaard, J. & Povlsen, C. O. Heterotransplantation of a human malignant tumour to "Nude" mice. Acta Pathol. Microbiol. Scand. 77, 758-760 (1969
89. Sausville, E. A. & Burger, A. M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 66, 3351-3354, (discussion 3354) (2006
90. Moro, M. et al. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. J. Biomed. Biotechnol. http://dx.doi.org/10.1155/ 2012/568567 (2012
91. Ito, R., Takahashi, T., Katano, I. & Ito, M. Current advances in humanized mouse models. Cell. Mol. Immunol. 9, 208-214 (2012
92. Zhao, H., Nolley, R., Chen, Z. & Peehl, D. M. Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am. J. Pathol. 177, 229-239 (2010
93. Fidler, I. J. Host and tumour factors in cancer metastasis. Eur. J. Clin. Invest. 20, 481-486 (1990
94. Pettaway, C. A. et al. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin. Cancer Res. 2, 1627-1636 (1996
95. Hoffman, R. M. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest. New Drugs 17, 343-359 (1999
96. Fidler, I. J. Biological heterogeneity of cancer: implication to therapy. Hum. Vaccin Immunother. 8, 1141-1142 (2012
97. Langley, R. R. & Fidler, I. J. The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer 128, 2527-2535 (2011). This review describes the favourable tumour-stroma interactions that underlie the organ-preference pattern of metastasis that is observed in cancer.
98. Scheer, N. & Roland Wolf, C. Xenobiotic receptor humanized mice and their utility. Drug Metab. Rev. 45, 110-121(2012
99. Friedl, P. & Alexander, S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147, 992-1009 (2011
100. Friedl, P., Locker, J., Sahai, E. & Segall, J. E. Classifying collective cancer cell invasion. Nature Cell Biol. 14, 777-783 (2012). This is a proposed framework for studying collective invasion.
101. Neeman, M., Gilad, A. A., Dafni, H. & Cohen, B. Molecular imaging of angiogenesis. J. Magn. Reson. Imag. 25, 1-12 (2007
102. Vandoorne, K., Addadi, Y. & Neeman, M. Visualizing vascular permeability and lymphatic drainage using labeled serum albumin. Angiogenesis 13, 75-85 (2010
103. Nemati, F. et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin. Cancer Res. 16, 2352-2362 (2010
104. Press, J. Z. et al. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol. Oncol. 110, 256-264 (2008
105. van Weerden, W. M. & van Steenbrugge, G. J. Human prostate tumor xenografts as representative models for clinical prostate cancer. Urol. Oncol. 2, 122-125 (1996
106. Jin, K. et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin. Transl. Oncol. 12, 473-480 (2010
107. Fu, X., Guadagni, F. & Hoffman, R. M. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc. Natl Acad. Sci. USA 89, 5645-5649 (1992
108. Fu, X. Y., Besterman, J. M., Monosov, A. & Hoffman, R. M. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc. Natl Acad. Sci. USA 88, 9345-9349 (1991
109. Metildi, C. A. et al. Fluorescently labeled chimeric anti-CEA antibody improves detection and resection of human colon cancer in a patient-derived orthotopic xenograft (PDOX) nude mouse model. J. Surg. Oncol. 109, 451-458 (2014
110. Berger, D. P., Winterhalter, B. R. & Fiebig, H. H. in Immunodeficient mice in oncology, Vol. 42 (eds Fiebig, H. H. & Berger, D. P.) 23-46 (Karger, 1992
111. Vlietstra, R. J., van Alewijk, D. C., Hermans, K. G.,van Steenbrugge, G. J. & Trapman, J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 58, 2720-2723 (1998
112. Kerbel, R. S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol. Ther. 2, S134-S139 (2003
113. Fichtner, I. et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin. Cancer Res. 14, 6456-6468 (2008
114. Hermans, K. G. et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 66, 10658-10663 (2006
115. DeRose, Y. S. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nature Med. 17, 1514-1520 (2011
116. Bankert, R. B. et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS ONE 6, e24420 (2011
117. Garcia, S. & Freitas, A. A. Humanized mice: current states and perspectives. Immunol. Lett. 146, 1-7 (2012).
118. Shultz, L. D., Brehm, M. A., Bavari, S. & Greiner, D. L. Humanized mice as a preclinical tool for infectious disease and biomedical research. Ann. NY Acad. Sci. 1245, 50-54 (2011
119. Shultz, L. D., Ishikawa, F. & Greiner, D. L. Humanized mice in translational biomedical research. Nature Rev. Immunol. 7, 118-130 (2007
120. Montecinos, V. P., Godoy, A., Hinklin, J., Vethanayagam, R. R. & Smith, G. J. Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma. PLoS ONE 7, e29623 (2012
121. Wang, Y. et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 64, 149-159 (2005
122. Simpson-Abelson, M. R. et al. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rγ(null) mice. J. Immunol. 180, 7009-7018 (2008
123. Ito, R. et al. Antigen-specific antibody production of human B cells in NOG mice reconstituted with the human immune system. Curr. Top. Microbiol. Immunol. 324, 95-107 (2008
124. Ji, M., Jin, X., Phillips, P. & Yi, S. A humanized mouse model to study human immune response in xenotransplantation. Hepatobiliary Pancreat. Dis. Int. 11, 494-498 (2012
125. van Miltenburg, M. H. & Jonkers, J. Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. Curr. Opin. Genet. Dev. 22, 21-27 (2012). This review highlights the recent technological advances in modelling cancer in GEMMs, their usefulness and the challenges encountered.
126. Walrath, J. C., Hawes, J. J., Van Dyke, T. & Reilly, K. M. Genetically engineered mouse models in cancer research. Adv. Cancer Res. 106, 113-164 (2010
127. Eklund, L., Bry, M. & Alitalo, K. Mouse models for studying angiogenesis and lymphangiogenesis in cancer. Mol. Oncol. 7, 259-282 (2013
128. Firestone, B. The challenge of selecting the ?right? in vivo oncology pharmacology model. Curr. Opin. Pharmacol. 10, 391-396 (2010
129. Schaffer, B. S. et al. Immune competency of a hairless mouse strain for improved preclinical studies in genetically engineered mice. Mol. Cancer Ther. 9, 2354-2364 (2010
130. Naumov, G. N. et al. Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy, to monitor steps in tumor metastasis. J. Cell Sci. 112, 1835-1842 (1999
131. Yang, M. et al. Direct external imaging of nascent cancer, tumor progression, angiogenesis, and metastasis on internal organs in the fluorescent orthotopic model. Proc. Natl Acad. Sci. USA 99, 3824-3829 (2002
132. Yang, M., Jiang, P. & Hoffman, R. M. Whole-body subcellular multicolor imaging of tumor-host interaction and drug response in real time. Cancer Res. 67, 5195-5200 (2007
133. Hoffman, R. M. Imaging cancer dynamics in vivo at the tumor and cellular level with fluorescent proteins. Clin. Exp. Metastasis 26, 345-355 (2009
134. Yamamoto, N., Tsuchiya, H. & Hoffman, R. M. Tumor imaging with multicolor fluorescent protein expression. Int. J. Clin. Oncol. 16, 84-91 (2011
135. Nothdurft, R., Sarder, P., Bloch, S., Culver, J. & Achilefu, S. Fluorescence lifetime imaging microscopy using near-infrared contrast agents. J. Microsc. 247, 202-207 (2012
136. Lin, M. Z. et al. Autofluorescent proteins with excitation in the optical window for intravital imaging in mammals. Chem. Biol. 16, 1169-1179 (2009
137. Morozova, K. S. et al. Far-red fluorescent protein excitable with red lasers for flow cytometry and superresolution STED nanoscopy. Biophys. J. 99, L13-15 (2010
138. Shcherbo, D. et al. Far-red fluorescent tags for protein imaging in living tissues. Biochem. J. 418, 567-574 (2009
139. Shcherbo, D. et al. Near-infrared fluorescent proteins. Nature Methods 7, 827-829 (2010). This paper describes the development of NIRF proteins with red-shifted emission maxima and high photostability for in vivo imaging.
140. Strack, R. L. et al. A rapidly maturing far-red derivative of DsRed-Express2 for whole-cell labeling. Biochemistry 48, 8279-8281 (2009
141. Beerling, E., Ritsma, L., Vrisekoop, N., Derksen, P. W. & van Rheenen, J. Intravital microscopy: new insights into metastasis of tumors. J. Cell Sci. 124, 299-310 (2011
142. Ritsma, L. et al. Intravital microscopy through an abdominal imaging window reveals a pre-micrometastasis stage during liver metastasis. Sci. Transl. Med. 4, 158ra145 (2012
143. Souris, J. S., Hickson, J. A., Msezane, L., Rinker-Schaeffer, C. W. & Chen, C. T. Flexible peritoneal windows for quantitative fluorescence and bioluminescence preclinical imaging. Mol. Imag. 12, 28-38 (2013
144. Tanaka, K. et al. Intravital dual-colored visualization of colorectal liver metastasis in living mice using two photon laser scanning microscopy. Microsc. Res. Tech. 75, 307-315 (2012
145. Amoh, Y., Katsuoka, K. & Hoffman, R. M. Color-coded fluorescent protein imaging of angiogenesis: the AngioMouse models. Curr. Pharm. Des. 14, 3810-3819 (2008
146. van der Horst, G. et al. Real-time cancer cell tracking by bioluminescence in a preclinical model of human bladder cancer growth and metastasis. Eur. Urol. 60, 337-343 (2011
147. Durupt, F. et al. The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses. Cancer Gene Ther. 19, 58-68 (2012
148. Harma, V. et al. A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS ONE 5, e10431 (2010
149. Sato, T. & Clevers, H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 340, 1190-1194 (2013
150. Sachs, N. & Clevers, H. Organoid cultures for the analysis of cancer phenotypes. Curr. Opin. Genet. Dev. 24C, 68-73 (2014
151. Fiebig, H. H. et al. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs. Cancer Genomics Proteomics 4, 197-209 (2007
152. Parrish, A. R., Gandolfi, A. J. & Brendel, K. Precision-cut tissue slices: applications in pharmacology and toxicology. Life Sci. 57, 1887-1901 (1995
153. Pickl, M. & Ries, C. H. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 28, 461-468 (2009
154. Willoughby, H. W., Maughan, G. B., Tremblay, P. C. & Wood, N. Determination of individual human tumour sensitivity to antitumour agents by tissue-slice incubation. Can. J. Surg. 14, 406-409 (1971
155. Zschenker, O., Streichert, T., Hehlgans, S. & Cordes, N. Genome-wide gene expression analysis in cancer cells reveals 3D growth to affect ECM and processes associated with cell adhesion but not DNA repair. PLoS ONE 7, e34279 (2012
156. Keyaerts, M. et al. Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imaging. PLoS ONE 7, e30061 (2012
157. Fueger, B. J. et al. Impact of animal handling on the results of 18F-FDG PET studies in mice. J. Nucl. Med. 47, 999-1006 (2006
158. Emonds, K. M. et al. Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines? Eur. J. Nucl. Med. Mol. Imaging 38, 1842-1853 (2011
159. Gros, S. J. et al. Complementary use of fluorescence and magnetic resonance imaging of metastatic esophageal cancer in a novel orthotopic mouse model. Int. J. Cancer 126, 2671-2681 (2010
160. Kosaka, N., Bernardo, M., Mitsunaga, M., Choyke, P. L. & Kobayashi, H. MR and optical imaging of early micrometastases in lymph nodes: triple labeling with nano-sized agents yielding distinct signals. Contrast Media Mol. Imag. 7, 247-253 (2012
161. Krupnick, A. S. et al. Quantitative monitoring of mouse lung tumors by magnetic resonance imaging. Nature Protoc. 7, 128-142 (2012
162. Wolf, G. & Abolmaali, N. Preclinical molecular imaging using PET and MRI. Recent Results Cancer Res. 187, 257-310 (2013
163. Pittet, M. J. & Weissleder, R. Intravital imaging. Cell 147, 983-991 (2011). This is an overview of state-of-the-art intravital imaging techniques and emerging technologies in this field.
164. Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555-1577 (2010
165. Festing, M. F. Improving the design and analysis of animal experiments: a personal odyssey. Altern. Lab. Anim. 37 (Suppl. 2), 75-81 (2009
166. Festing, M. F. Inbred strains should replace outbred stocks in toxicology, safety testing, and drug development. Toxicol. Pathol. 38, 681-690 (2010
167. Klaunberg, B. A. & Davis, J. A. Considerations for laboratory animal imaging center design and setup. ILAR J. 49, 4-16 (2008
168. Maina, T. et al. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J. Nucl. Med. 46, 823-830 (2005
169. Wagner, P. D. & Srivastava, S. New paradigms in translational science research in cancer biomarkers. Transl. Res. 159, 343-353 (2012). This is a perspective on cancer biomarker translation.
170. Roberts, S. F., Fischhoff, M. A., Sakowski, S. A. & Feldman, E. L. Perspective: Transforming science into medicine: how clinician-scientists can build bridges across research?s valley of death. Acad. Med. 87, 266-270 (2012
171. Caponigro, G. & Sellers, W. R. Advances in the preclinical testing of cancer therapeutic hypotheses. Nature Rev. Drug Discov. 10, 179-187 (2011
172. Feitsma, H. & Cuppen, E. Zebrafish as a cancer model. Mol. Cancer Res. 6, 685-694 (2008
173. Ale, A. et al. FMT-XCT: in vivo animal studies with hybrid fluorescence molecular tomography-X-ray computed tomography. Nature Methods 9, 615-620 (2012
174. Afaq, A. & Akin, O. Imaging assessment of tumor response: past, present and future. Future Oncol. 7, 669-677 (2011).